Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control Arm Solution to Accelerate Brain Cancer Clinical Trial (GlobeNewswire) - Feb 22, 2022 - "Plus Therapeutics...announced a partnership with Medidata, a Dassault Systèmes company, to evaluate the use of its Synthetic Control Arm® (SCA) solution in a planned Phase 2 trial of Rhenium-186 NanoLiposome (186RNL) in recurrent glioblastoma (GBM), a type of brain cancer....The SCA enables study designs that have a higher than usual probability of assignment of prospective patients to the investigational therapy. This enhances patient enrollment and retention and potentially reduces clinical trial costs while upholding the scientific integrity of the trial."
Licensing / partnership • New P2 trial • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|